The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving ...
In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13 ...
Despite some angst over pricing pressure for GLP-1 drugs, Lilly’s bullish projections surpassed consensus estimates, while ...
The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a ...
CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...
Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...
AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...
Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...
On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” surrounding Elevidys.
Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results